201
|
Lima TC, Souza RJ, Santos ADC, Moraes MH, Biondo NE, Barison A, Steindel M, Biavatti MW. Evaluation of leishmanicidal and trypanocidal activities of phenolic compounds from Calea uniflora Less. Nat Prod Res 2015; 30:551-7. [PMID: 25880257 DOI: 10.1080/14786419.2015.1030740] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The phytochemical study of Calea uniflora led to the isolation of nine phenolic compounds identified as noreugenin (1), ethyl caffeate (2), a mixture of butein (3) + orobol (4), α-hydroxy-butein (5), caffeic acid (6), butein 4'-O-glucopyranosyl (7), quercetin 3-O-glucopyranosyl (8) and 3,5-di-O-caffeoylquinic acid (9). The chemical identity of the isolates was established on the basis of NMR and physical data. The chemical shifts of 5 and 7 have been reassigned and all the isolates were tested against Leishmania amazonensis and Trypanosoma cruzi amastigotes. None of the metabolites showed promising leishmanicidal activity. However, 2 and the mixture of 3 and 4 demonstrated interesting trypanocidal effect with IC50 values of 18.27 and 26.53 μM, respectively. Besides, these compounds did not present cytotoxic effect towards THP-1 cells, and compound 2 was 3.5-fold more selective than the mixture of 3+4.
Collapse
Affiliation(s)
- Tamires C Lima
- a Departamento de Ciências Farmacêuticas, CCS , Universidade Federal de Santa Catarina (UFSC) , Florianópolis , SC , Brazil
| | - Rafaela J Souza
- a Departamento de Ciências Farmacêuticas, CCS , Universidade Federal de Santa Catarina (UFSC) , Florianópolis , SC , Brazil
| | - Alan D C Santos
- b Departamento de Química , Universidade Federal do Paraná (UFPR) , Curitiba , PR , Brazil
| | - Milene H Moraes
- c Departamento de Microbiologia e Parasitologia, CCB , Universidade Federal de Santa Catarina (UFSC) , Florianópolis , SC , Brazil
| | - Nicole E Biondo
- c Departamento de Microbiologia e Parasitologia, CCB , Universidade Federal de Santa Catarina (UFSC) , Florianópolis , SC , Brazil
| | - Andersson Barison
- b Departamento de Química , Universidade Federal do Paraná (UFPR) , Curitiba , PR , Brazil
| | - Mário Steindel
- c Departamento de Microbiologia e Parasitologia, CCB , Universidade Federal de Santa Catarina (UFSC) , Florianópolis , SC , Brazil
| | - Maique W Biavatti
- a Departamento de Ciências Farmacêuticas, CCS , Universidade Federal de Santa Catarina (UFSC) , Florianópolis , SC , Brazil
| |
Collapse
|
202
|
Peña I, Pilar Manzano M, Cantizani J, Kessler A, Alonso-Padilla J, Bardera AI, Alvarez E, Colmenarejo G, Cotillo I, Roquero I, de Dios-Anton F, Barroso V, Rodriguez A, Gray DW, Navarro M, Kumar V, Sherstnev A, Drewry DH, Brown JR, Fiandor JM, Julio Martin J. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci Rep 2015; 5:8771. [PMID: 25740547 PMCID: PMC4350103 DOI: 10.1038/srep08771] [Citation(s) in RCA: 181] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 01/28/2015] [Indexed: 12/11/2022] Open
Abstract
Using whole-cell phenotypic assays, the GlaxoSmithKline high-throughput screening (HTS) diversity set of 1.8 million compounds was screened against the three kinetoplastids most relevant to human disease, i.e. Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Secondary confirmatory and orthogonal intracellular anti-parasiticidal assays were conducted, and the potential for non-specific cytotoxicity determined. Hit compounds were chemically clustered and triaged for desirable physicochemical properties. The hypothetical biological target space covered by these diversity sets was investigated through bioinformatics methodologies. Consequently, three anti-kinetoplastid chemical boxes of ~200 compounds each were assembled. Functional analyses of these compounds suggest a wide array of potential modes of action against kinetoplastid kinases, proteases and cytochromes as well as potential host–pathogen targets. This is the first published parallel high throughput screening of a pharma compound collection against kinetoplastids. The compound sets are provided as an open resource for future lead discovery programs, and to address important research questions.
Collapse
Affiliation(s)
- Imanol Peña
- Molecular Discovery Research, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - M Pilar Manzano
- Diseases of the Developing World (DDW), Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Juan Cantizani
- Diseases of the Developing World (DDW), Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Albane Kessler
- Diseases of the Developing World (DDW), Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Julio Alonso-Padilla
- Department of Microbiology, Division of Parasitology, New York University School of Medicine, New York, NY, USA
| | - Ana I Bardera
- Molecular Discovery Research, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Emilio Alvarez
- Molecular Discovery Research, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Gonzalo Colmenarejo
- Molecular Discovery Research, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Ignacio Cotillo
- Diseases of the Developing World (DDW), Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Irene Roquero
- Molecular Discovery Research, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Francisco de Dios-Anton
- Molecular Discovery Research, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Vanessa Barroso
- Molecular Discovery Research, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - Ana Rodriguez
- Department of Microbiology, Division of Parasitology, New York University School of Medicine, New York, NY, USA
| | - David W Gray
- Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, UK
| | - Miguel Navarro
- Instituto de Parasitología y Biomedicina "López-Neyra" Consejo Superior de Investigaciones Cientificas, Granada, Spain
| | - Vinod Kumar
- Computational Biology, Quantitative Sciences, GlaxoSmithKline, Collegeville, PA, USA
| | - Alexander Sherstnev
- Computational Biology, Quantitative Sciences, GlaxoSmithKline, Medicines Research Center, Stevenage, Hertfordshire, UK
| | - David H Drewry
- Chemical Sciences, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, NC, USA
| | - James R Brown
- Computational Biology, Quantitative Sciences, GlaxoSmithKline, Collegeville, PA, USA
| | - Jose M Fiandor
- Diseases of the Developing World (DDW), Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| | - J Julio Martin
- Molecular Discovery Research, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
| |
Collapse
|
203
|
Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases rhodesain, cruzain, and Schistosoma mansoni cathepsin B1. Antimicrob Agents Chemother 2015; 59:2666-77. [PMID: 25712353 DOI: 10.1128/aac.04601-14] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Accepted: 02/02/2015] [Indexed: 01/27/2023] Open
Abstract
The pressing need for better drugs against Chagas disease, African sleeping sickness, and schistosomiasis motivates the search for inhibitors of cruzain, rhodesain, and Schistosoma mansoni CB1 (SmCB1), the major cysteine proteases from Trypanosoma cruzi, Trypanosoma brucei, and S. mansoni, respectively. Thiosemicarbazones and heterocyclic analogues have been shown to be both antitrypanocidal and inhibitory against parasite cysteine proteases. A series of compounds was synthesized and evaluated against cruzain, rhodesain, and SmCB1 through biochemical assays to determine their potency and structure-activity relationships (SAR). This approach led to the discovery of 6 rhodesain, 4 cruzain, and 5 SmCB1 inhibitors with 50% inhibitory concentrations (IC50s) of ≤ 10 μM. Among the compounds tested, the thiosemicarbazone derivative of peracetylated galactoside (compound 4i) was discovered to be a potent rhodesain inhibitor (IC50 = 1.2 ± 1.0 μM). The impact of a range of modifications was determined; removal of thiosemicarbazone or its replacement by semicarbazone resulted in virtually inactive compounds, and modifications in the sugar also diminished potency. Compounds were also evaluated in vitro against the parasites T. cruzi, T. brucei, and S. mansoni, revealing active compounds among this series.
Collapse
|
204
|
Insuasty B, Ramírez J, Becerra D, Echeverry C, Quiroga J, Abonia R, Robledo SM, Vélez ID, Upegui Y, Muñoz JA, Ospina V, Nogueras M, Cobo J. An efficient synthesis of new caffeine-based chalcones, pyrazolines and pyrazolo[3,4-b][1,4]diazepines as potential antimalarial, antitrypanosomal and antileishmanial agents. Eur J Med Chem 2015; 93:401-13. [PMID: 25725376 DOI: 10.1016/j.ejmech.2015.02.040] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Revised: 02/19/2015] [Accepted: 02/20/2015] [Indexed: 12/15/2022]
Abstract
A new series of chalcones 5a-f were synthesized from caffeine-based aldehyde 3 and substituted acetophenones 4a-f. Treatment of compounds 5a-f with hydrazine hydrate led to pyrazolines 6a-f, and their subsequent reaction with acetic anhydride or formic acid afforded the corresponding N-substituted pyrazolines 7a-f and 8a-f respectively. Additionally, the regioselective cyclocondensation reaction of chalcones 5a-f with 4,5-diaminopyrazole 9 afforded the diazepine derivatives 10a-f. Synthesis of the above novel compounds was carried out through a simple procedure involving an easy work-up and mild reaction conditions. In vitro antimalarial activity against Plasmodium falciparum was evaluated for the obtained compounds. Among of them, just pirazoline 6a showed an outstanding growth inhibition percentage 85.2 ± 5.4%, while diazepines 10a-f showed remarkable growth inhibitions in the range of 80.3 ± 13.5 to 94.2 ± 0.2% when were tested at 20 μg/mL. Compounds 5b, 5e, 7c and 7f showed remarkable activities against Leishmania panamensis with growth inhibition of 88.3 ± 1.5, 82.6 ± 2.2, 82.8 ± 1.7 and 87.6 ± 0.5% respectively, at 20 μg/mL. In vitro assays against Trypanozoma cruzi showed that pyrazoline 6d displayed a growth inhibition of 61.9 ± 7.8% at 20 μg/mL while chalcone 5f was considered especially active with a growth inhibition of 9.7 ± 1.5% for a very low concentration of 1.0 μg/mL.
Collapse
Affiliation(s)
- Braulio Insuasty
- Grupo de Investigación de Compuestos Heterocíclicos, Departamento de Química, Universidad del Valle, A. A. 25360 Cali, Colombia.
| | - Juan Ramírez
- Grupo de Investigación de Compuestos Heterocíclicos, Departamento de Química, Universidad del Valle, A. A. 25360 Cali, Colombia
| | - Diana Becerra
- Grupo de Investigación de Compuestos Heterocíclicos, Departamento de Química, Universidad del Valle, A. A. 25360 Cali, Colombia
| | - Carlos Echeverry
- Grupo de Investigación de Compuestos Heterocíclicos, Departamento de Química, Universidad del Valle, A. A. 25360 Cali, Colombia
| | - Jairo Quiroga
- Grupo de Investigación de Compuestos Heterocíclicos, Departamento de Química, Universidad del Valle, A. A. 25360 Cali, Colombia
| | - Rodrigo Abonia
- Grupo de Investigación de Compuestos Heterocíclicos, Departamento de Química, Universidad del Valle, A. A. 25360 Cali, Colombia
| | - Sara M Robledo
- PECET, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, PO Box 1226, Medellín, Colombia
| | - Iván Darío Vélez
- PECET, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, PO Box 1226, Medellín, Colombia
| | - Yulieth Upegui
- PECET, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, PO Box 1226, Medellín, Colombia
| | - July A Muñoz
- PECET, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, PO Box 1226, Medellín, Colombia
| | - Victoria Ospina
- PECET, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, PO Box 1226, Medellín, Colombia
| | - Manuel Nogueras
- Department of Inorganic and Organic Chemistry, Universidad de Jaén, 23071 Jaén, Spain
| | - Justo Cobo
- Department of Inorganic and Organic Chemistry, Universidad de Jaén, 23071 Jaén, Spain
| |
Collapse
|
205
|
Kaiser M, Maes L, Tadoori LP, Spangenberg T, Ioset JR. Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids. ACTA ACUST UNITED AC 2015; 20:634-45. [PMID: 25690568 DOI: 10.1177/1087057115569155] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Accepted: 01/02/2015] [Indexed: 01/06/2023]
Abstract
Phenotypic screening had successfully been used for hit generation, especially in the field of neglected diseases, in which feeding the drug pipeline with new chemotypes remains a constant challenge. Here, we catalyze drug discovery research using a publicly available screening tool to boost drug discovery. The Malaria Box, assembled by the Medicines for Malaria Venture, is a structurally diverse set of 200 druglike and 200 probelike compounds distilled from more than 20,000 antimalarial hits from corporate and academic libraries. Repurposing such compounds has already identified new scaffolds against cryptosporidiosis and schistosomiasis. In addition to initiating new hit-to-lead activities, screening the Malaria Box against a plethora of other parasites would enable the community to better understand the similarities and differences between them. We describe the screening of the Malaria Box and triaging of the identified hits against kinetoplastids responsible for human African trypanosomiasis (Trypanosoma brucei), Chagas disease (Trypanosoma cruzi), and visceral leishmaniasis (Leishmania donovani and Leishmania infantum). The in vitro and in vivo profiling of the most promising active compounds with respect to efficacy, toxicity, pharmacokinetics, and complementary druggable properties are presented and a collaborative model used as a way to accelerate the discovery process discussed.
Collapse
Affiliation(s)
- Marcel Kaiser
- Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland
| | - Louis Maes
- Laboratory of Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Antwerp, Belgium
| | | | | | | |
Collapse
|
206
|
Montalvo-Quirós S, Taladriz-Sender A, Kaiser M, Dardonville C. Antiprotozoal activity and DNA binding of dicationic acridones. J Med Chem 2015; 58:1940-9. [PMID: 25642604 DOI: 10.1021/jm5018303] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Dicationic acridone derivatives were synthesized and their antiparasitic activity was evaluated. Acridones displayed in vitro nanomolar IC50 values against Trypanosoma brucei rhodesiense STIB900 with selectivity indices >1000. Compounds 1b, 3a, and 3b were as potent as the reference drug melarsoprol in this assay. Submicromolar-range activities were observed against wild-type (NF54) and resistant (K1) strains of Plasmodium falciparum, whereas no significant activity was detected against Trypanosoma cruzi or Leishmania donovani. Compounds 1a and 1b were curative in the STIB900 mouse model for human African trypanosomiasis. UV spectrophotometric titrations and circular dichroism (CD) experiments with fish sperm (FS) DNA showed that these compounds form complexes with DNA with binding affinities in the 10(4) M(-1) range. Biological and biophysical data show that antiparasitic activity, toxicity, and DNA binding of this series of acridones are dependent on the relative position of both imidazolinium cations on the heterocyclic scaffold.
Collapse
Affiliation(s)
- Sandra Montalvo-Quirós
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC) , Juan de la Cierva 3, E-28006 Madrid, Spain
| | | | | | | |
Collapse
|
207
|
Novel solid dispersions of benznidazole: Preparation, dissolution profile and biological evaluation as alternative antichagasic drug delivery system. Exp Parasitol 2015; 149:84-91. [DOI: 10.1016/j.exppara.2015.01.002] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 12/02/2014] [Accepted: 01/04/2015] [Indexed: 11/21/2022]
|
208
|
Alonso-Padilla J, Cotillo I, Presa JL, Cantizani J, Peña I, Bardera AI, Martín JJ, Rodriguez A. Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line. PLoS Negl Trop Dis 2015; 9:e0003493. [PMID: 25615687 PMCID: PMC4304841 DOI: 10.1371/journal.pntd.0003493] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Accepted: 12/23/2014] [Indexed: 11/23/2022] Open
Abstract
Background Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, represents a very important public health problem in Latin America where it is endemic. Although mostly asymptomatic at its initial stage, after the disease becomes chronic, about a third of the infected patients progress to a potentially fatal outcome due to severe damage of heart and gut tissues. There is an urgent need for new drugs against Chagas disease since there are only two drugs available, benznidazole and nifurtimox, and both show toxic side effects and variable efficacy against the chronic stage of the disease. Methodology/Principal Findings Genetically engineered parasitic strains are used for high throughput screening (HTS) of large chemical collections in the search for new anti-parasitic compounds. These assays, although successful, are limited to reporter transgenic parasites and do not cover the wide T. cruzi genetic background. With the aim to contribute to the early drug discovery process against Chagas disease we have developed an automated image-based 384-well plate HTS assay for T. cruzi amastigote replication in a rat myoblast host cell line. An image analysis script was designed to inform on three outputs: total number of host cells, ratio of T. cruzi amastigotes per cell and percentage of infected cells, which respectively provides one host cell toxicity and two T. cruzi toxicity readouts. The assay was statistically robust (Z´ values >0.6) and was validated against a series of known anti-trypanosomatid drugs. Conclusions/Significance We have established a highly reproducible, high content HTS assay for screening of chemical compounds against T. cruzi infection of myoblasts that is amenable for use with any T. cruzi strain capable of in vitro infection. Our visual assay informs on both anti-parasitic and host cell toxicity readouts in a single experiment, allowing the direct identification of compounds selectively targeted to the parasite. Chagas disease is a zoonosis caused by the protozoan parasite Trypanosoma cruzi. Endemic to Central and South America, it affects over 10 million people and many more live in risk transmission areas. Although mostly asymptomatic at its initial acute stage in humans, damages can occur over the years in many tissues such as T. cruzi-hosting heart and digestive track. For over 40 years the chemotherapy of Chagas disease has relied on the use of two drugs, benznidazole and nifurtimox, though both are known to lead to severe side effects which often prompt to the discontinuation of the treatments. Despite having good efficacy against the acute stage of infection, its efficacy against the chronic stage is under question. Therefore, there is an urgent unmet need of new anti-T. cruzi drugs. Several efforts have been made in the last years to establish reliable high throughput cell based in vitro assays to be used for drug discovery against Chagas. With the aim to contribute to this field here we describe the development of a new automated image-based assay to identify new compounds against T. cruzi that has been set up using the myoblastic rat cell line H9c2 as cell-cycling amastigotes hosting cells.
Collapse
Affiliation(s)
- Julio Alonso-Padilla
- Parasitology Division, Department of Microbiology, New York University School of Medicine, New York, New York, United States of America
| | - Ignacio Cotillo
- Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain
| | - Jesús L. Presa
- Molecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain
| | - Juan Cantizani
- Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain
| | - Imanol Peña
- Molecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain
| | - Ana I. Bardera
- Molecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain
| | - Jose J. Martín
- Molecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain
| | - Ana Rodriguez
- Parasitology Division, Department of Microbiology, New York University School of Medicine, New York, New York, United States of America
- * E-mail:
| |
Collapse
|
209
|
Campos FF, Sales Junior PA, Romanha AJ, Araújo MSS, Siqueira EP, Resende JM, Alves TMA, Martins-Filho OA, Santos VLD, Rosa CA, Zani CL, Cota BB. Bioactive endophytic fungi isolated from Caesalpinia echinata Lam. (Brazilwood) and identification of beauvericin as a trypanocidal metabolite from Fusarium sp. Mem Inst Oswaldo Cruz 2015; 110:65-74. [PMID: 25742265 PMCID: PMC4371219 DOI: 10.1590/0074-02760140243] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2014] [Accepted: 11/28/2014] [Indexed: 12/20/2022] Open
Abstract
Aiming to identify new sources of bioactive secondary metabolites, we isolated 82
endophytic fungi from stems and barks of the native Brazilian tree Caesalpinia
echinata Lam. (Fabaceae). We tested their ethyl acetate extracts in several in vitro
assays. The organic extracts from three isolates showed antibacterial activity
against Staphylococcus aureus and Escherichia coli [minimal inhibitory concentration
(MIC) 32-64 μg/mL]. One isolate inhibited the growth of Salmonella typhimurium (MIC
64 μg/mL) and two isolates inhibited the growth of Klebsiella oxytoca (MIC 64 μg/mL),
Candida albicans and Candida tropicalis (MIC 64-128 μg/mL). Fourteen extracts at a
concentration of 20 μg/mL showed antitumour activities against human breast cancer
and human renal cancer cells, while two isolates showed anti-tumour activities
against human melanoma cancer cells. Six extracts were able to reduce the
proliferation of human peripheral blood mononuclear cells, indicating some degree of
selective toxicity. Four isolates were able to inhibit Leishmania (Leishmania)
amazonensis and one isolate inhibited Trypanosoma cruzi by at least 40% at 20 μg/mL.
The trypanocidal extract obtained from Fusarium sp. [KF611679] culture was subjected
to bioguided fractionation, which revealed beauvericin as the compound responsible
for the observed toxicity of Fusarium sp. to T. cruzi. This depsipeptide showed a
half maximal inhibitory concentration of 1.9 μg/mL (2.43 μM) in a T. cruzi cellular
culture assay.
Collapse
Affiliation(s)
- Fernanda Fraga Campos
- Departamento de Ciências Biológicas e da Saúde, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, MG, Brasil
| | | | | | | | | | | | - Tânia M A Alves
- Centro de Pesquisas René Rachou-Fiocruz, Belo Horizonte, MG, Brasil
| | | | - Vera Lúcia dos Santos
- Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil
| | - Carlos A Rosa
- Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil
| | - Carlos L Zani
- Centro de Pesquisas René Rachou-Fiocruz, Belo Horizonte, MG, Brasil
| | | |
Collapse
|
210
|
Abstract
The discovery of new therapeutic options against Trypanosoma cruzi, the causative agent of Chagas disease, stands as a fundamental need. Currently, there are only two drugs available to treat this neglected disease, which represents a major public health problem in Latin America. Both available therapies, benznidazole and nifurtimox, have significant toxic side effects and their efficacy against the life-threatening symptomatic chronic stage of the disease is variable. Thus, there is an urgent need for new, improved anti–T. cruzi drugs. With the objective to reliably accelerate the drug discovery process against Chagas disease, several advances have been made in the last few years. Availability of engineered reporter gene expressing parasites triggered the development of phenotypic in vitro assays suitable for high throughput screening (HTS) as well as the establishment of new in vivo protocols that allow faster experimental outcomes. Recently, automated high content microscopy approaches have also been used to identify new parasitic inhibitors. These in vitro and in vivo early drug discovery approaches, which hopefully will contribute to bring better anti–T. cruzi drug entities in the near future, are reviewed here.
Collapse
|
211
|
Choi JY, Podust LM, Roush WR. Drug strategies targeting CYP51 in neglected tropical diseases. Chem Rev 2014; 114:11242-71. [PMID: 25337991 PMCID: PMC4254036 DOI: 10.1021/cr5003134] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2014] [Indexed: 01/04/2023]
Affiliation(s)
- Jun Yong Choi
- Department
of Chemistry, Scripps Florida, 130 Scripps Way, Jupiter, Florida 33458, United States
| | - Larissa M. Podust
- Center for Discovery and Innovation in Parasitic Diseases, and Department of
Pathology, University of California—San
Francisco, San Francisco, California 94158, United States
| | - William R. Roush
- Department
of Chemistry, Scripps Florida, 130 Scripps Way, Jupiter, Florida 33458, United States
| |
Collapse
|
212
|
A new nonpolar N-hydroxy imidazoline lead compound with improved activity in a murine model of late-stage Trypanosoma brucei brucei infection is not cross-resistant with diamidines. Antimicrob Agents Chemother 2014; 59:890-904. [PMID: 25421467 DOI: 10.1128/aac.03958-14] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Treatment of late-stage sleeping sickness requires drugs that can cross the blood-brain barrier (BBB) to reach the parasites located in the brain. We report here the synthesis and evaluation of four new N-hydroxy and 12 new N-alkoxy derivatives of bisimidazoline leads as potential agents for the treatment of late-stage sleeping sickness. These compounds, which have reduced basicity compared to the parent leads (i.e., are less ionized at physiological pH), were evaluated in vitro against Trypanosoma brucei rhodesiense and in vivo in murine models of first- and second-stage sleeping sickness. Resistance profile, physicochemical parameters, in vitro BBB permeability, and microsomal stability also were determined. The N-hydroxy imidazoline analogues were the most effective in vivo, with 4-((1-hydroxy-4,5-dihydro-1H-imidazol-2-yl)amino)-N-(4-((1-hydroxy-4,5-dihydro-1H-imidazol-2-yl)amino)phenyl)benzamide (14d) showing 100% cures in the first-stage disease, while 15d, 16d, and 17d appeared to slightly improve survival. In addition, 14d showed weak activity in the chronic model of central nervous system infection in mice. No evidence of reduction of this compound with hepatic microsomes and mitochondria was found in vitro, suggesting that N-hydroxy imidazolines are metabolically stable and have intrinsic activity against T. brucei. In contrast to its unsubstituted parent compound, the uptake of 14d in T. brucei was independent of known drug transporters (i.e., T. brucei AT1/P2 and HAPT), indicating a lower predisposition to cross-resistance with other diamidines and arsenical drugs. Hence, the N-hydroxy bisimidazolines (14d in particular) represent a new class of promising antitrypanosomal agents.
Collapse
|
213
|
Annang F, Pérez-Moreno G, García-Hernández R, Cordon-Obras C, Martín J, Tormo JR, Rodríguez L, de Pedro N, Gómez-Pérez V, Valente M, Reyes F, Genilloud O, Vicente F, Castanys S, Ruiz-Pérez LM, Navarro M, Gamarro F, González-Pacanowska D. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease. ACTA ACUST UNITED AC 2014; 20:82-91. [PMID: 25332350 DOI: 10.1177/1087057114555846] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
African trypanosomiasis, leishmaniasis, and Chagas disease are 3 neglected tropical diseases for which current therapeutic interventions are inadequate or toxic. There is an urgent need to find new lead compounds against these diseases. Most drug discovery strategies rely on high-throughput screening (HTS) of synthetic chemical libraries using phenotypic and target-based approaches. Combinatorial chemistry libraries contain hundreds of thousands of compounds; however, they lack the structural diversity required to find entirely novel chemotypes. Natural products, in contrast, are a highly underexplored pool of unique chemical diversity that can serve as excellent templates for the synthesis of novel, biologically active molecules. We report here a validated HTS platform for the screening of microbial extracts against the 3 diseases. We have used this platform in a pilot project to screen a subset (5976) of microbial extracts from the MEDINA Natural Products library. Tandem liquid chromatography-mass spectrometry showed that 48 extracts contain potentially new compounds that are currently undergoing de-replication for future isolation and characterization. Known active components included actinomycin D, bafilomycin B1, chromomycin A3, echinomycin, hygrolidin, and nonactins, among others. The report here is, to our knowledge, the first HTS of microbial natural product extracts against the above-mentioned kinetoplastid parasites.
Collapse
Affiliation(s)
- F Annang
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - G Pérez-Moreno
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - R García-Hernández
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - C Cordon-Obras
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - J Martín
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - J R Tormo
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - L Rodríguez
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - N de Pedro
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - V Gómez-Pérez
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - M Valente
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - F Reyes
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - O Genilloud
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - F Vicente
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - S Castanys
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - L M Ruiz-Pérez
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - M Navarro
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - F Gamarro
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| | - D González-Pacanowska
- Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Armilla (Granada), Spain
| |
Collapse
|
214
|
Brito SMO, Coutinho HDM, Talvani A, Coronel C, Barbosa AGR, Vega C, Figueredo FG, Tintino SR, Lima LF, Boligon AA, Athayde ML, Menezes IRA. Analysis of bioactivities and chemical composition of Ziziphus joazeiro Mart. using HPLC-DAD. Food Chem 2014; 186:185-91. [PMID: 25976809 DOI: 10.1016/j.foodchem.2014.10.031] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 10/03/2014] [Accepted: 10/05/2014] [Indexed: 01/17/2023]
Abstract
The aim of this study was to evaluate the chemical profile and antioxidant, antimicrobial and antiparasitic activities of the hydroalcoholic extract of the leaves of Ziziphus joazeiro Mart. (HELZJ). The antioxidant DPPH and FRAP assays and chemical profile were determined by colorimetric methods and HPLC/DAD. The antiparasitic, antibiotic and antibiotic-modifying activity were evaluated by microdilution assays. The HPLC-DAD assay showed the presence of mostly tannins and flavonoids, such as caffeic acid and quercetin. The levels of polyphenols and flavonoids were 183.136 mg/g extract and 7.37 mg/g extract, respectively. DPPH and FRAP showed low antioxidant activity for the extract. The antibacterial and antifungal activities were not of clinical relevance, showing MIC>1024 μg/mL. However, synergism was observed between HELZJ and the antibiotics amikacin and gentamicin, which resulted in decreased bacterial drug resistance. EHFZJ showed low toxicity in fibroblasts in vitro, while antiparasitic results against Trypnosoma cruzi, Leishmania braziliensis and Leishmania infantum were not clinically relevant. Thus, our results indicate that Z. joazeiro Mart. (HELZJ) could be a source of plant-derived natural products that could lead to the development of promising new antibiotic compounds for infectious diseases.
Collapse
Affiliation(s)
- Sharlene M O Brito
- Pharmacology and Medicinal Chemistry Laboratory, Department of Chemical Biology, Regional University of Cariri, Crato, Ceara, Brazil
| | - Henrique D M Coutinho
- Laboratory of Microbiology and Molecular Biology, Regional University of Cariri, Crato, Brazil.
| | - Andre Talvani
- Laboratory of Chagas Disease, Federal University of Ouro Preto, Ouro Preto, Brazil
| | - Cathia Coronel
- Phytochemical Research Laboratory, Department of Industrial Pharmacy, Federal University of Santa Maria, Santa Maria, Brazil
| | - Andreza G R Barbosa
- Pharmacology and Medicinal Chemistry Laboratory, Department of Chemical Biology, Regional University of Cariri, Crato, Ceara, Brazil
| | - Celeste Vega
- Phytochemical Research Laboratory, Department of Industrial Pharmacy, Federal University of Santa Maria, Santa Maria, Brazil
| | - Fernando G Figueredo
- Laboratory of Microbiology and Molecular Biology, Regional University of Cariri, Crato, Brazil
| | - Saulo R Tintino
- Laboratory of Microbiology and Molecular Biology, Regional University of Cariri, Crato, Brazil
| | - Luciene F Lima
- Laboratory of Microbiology and Molecular Biology, Regional University of Cariri, Crato, Brazil
| | - Aline A Boligon
- Centro para el Desarrollo de la Investigación Científica (CEDIC), Fundación Moisés Bertoni/Laboratorios Díaz Gill, Asunción, Paraguay
| | - Margareth L Athayde
- Centro para el Desarrollo de la Investigación Científica (CEDIC), Fundación Moisés Bertoni/Laboratorios Díaz Gill, Asunción, Paraguay
| | - Irwin R A Menezes
- Pharmacology and Medicinal Chemistry Laboratory, Department of Chemical Biology, Regional University of Cariri, Crato, Ceara, Brazil.
| |
Collapse
|
215
|
Neitz RJ, Chen S, Supek F, Yeh V, Kellar D, Gut J, Bryant C, Gallardo-Godoy A, Molteni V, Roach SL, Chatterjee AK, Robertson S, Renslo AR, Arkin M, Glynne R, McKerrow J, Siqueira-Neto JL. Lead Identification to Clinical Candidate Selection. ACTA ACUST UNITED AC 2014; 20:101-11. [DOI: 10.1177/1087057114553103] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Chagas disease affects 8 million people worldwide and remains a main cause of death due to heart failure in Latin America. The number of cases in the United States is now estimated to be 300,000, but there are currently no Food and Drug Administration (FDA)–approved drugs available for patients with Chagas disease. To fill this gap, we have established a public-private partnership between the University of California, San Francisco and the Genomics Institute of the Novartis Research Foundation (GNF) with the goal of delivering clinical candidates to treat Chagas disease. The discovery phase, based on the screening of more than 160,000 compounds from the GNF Academic Collaboration Library, led to the identification of new anti-Chagas scaffolds. Part of the screening campaign used and compared two screening methods, including a colorimetric-based assay using Trypanosoma cruzi expressing β-galactosidase and an image-based, high-content screening (HCS) assay using the CA-I/72 strain of T. cruzi. Comparing molecules tested in both assays, we found that ergosterol biosynthesis inhibitors had greater potency in the colorimetric assay than in the HCS assay. Both assays were used to inform structure-activity relationships for antiparasitic efficacy and pharmacokinetics. A new anti– T. cruzi scaffold derived from xanthine was identified, and we describe its development as lead series.
Collapse
Affiliation(s)
- R. Jeffrey Neitz
- Small Molecule Discovery Center and Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
| | - Steven Chen
- Small Molecule Discovery Center and Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
| | - Frantisek Supek
- Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, USA
| | - Vince Yeh
- Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, USA
| | - Danielle Kellar
- Center for Discovery and Innovation in Parasitic Diseases, University of California, San Francisco, CA, USA
- Department of Pathology, University of California, San Francisco, CA, USA
- Five Prime Therapeutics, San Francisco, CA, USA
| | - Jiri Gut
- Center for Discovery and Innovation in Parasitic Diseases, University of California, San Francisco, CA, USA
- Department of Pathology, University of California, San Francisco, CA, USA
| | - Clifford Bryant
- Small Molecule Discovery Center and Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
| | - Alejandra Gallardo-Godoy
- Small Molecule Discovery Center and Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
| | - Valentina Molteni
- Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, USA
| | - Steven L. Roach
- Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, USA
- Dart Neuroscience, San Diego, CA, USA
| | - Arnab K. Chatterjee
- Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, USA
- California Institute for Biomedical Research (Calibr), San Diego, CA, USA
| | - Stephanie Robertson
- Innovation, Technology, and Alliances, University of California, San Francisco, CA, USA
| | - Adam R. Renslo
- Small Molecule Discovery Center and Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
| | - Michelle Arkin
- Small Molecule Discovery Center and Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
| | - Richard Glynne
- Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, USA
| | - James McKerrow
- Center for Discovery and Innovation in Parasitic Diseases, University of California, San Francisco, CA, USA
- Department of Pathology, University of California, San Francisco, CA, USA
- Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, CA, USA
| | - Jair L. Siqueira-Neto
- Center for Discovery and Innovation in Parasitic Diseases, University of California, San Francisco, CA, USA
- Department of Pathology, University of California, San Francisco, CA, USA
- Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, CA, USA
| |
Collapse
|
216
|
Abstract
American trypanosomiasis, or Chagas disease, is the result of infection by the Trypanosoma cruzi parasite. Endemic in Latin America where it is the major cause of death from cardiomyopathy, the impact of the disease is reaching global proportions through migrating populations. New drugs that are safe, efficacious, low cost, and adapted to the field are critically needed. Over the past five years, there has been increased interest in the disease and a surge in activities within various organizations. However, recent clinical trials with azoles, specifically posaconazole and the ravuconazole prodrug E1224, were disappointing, with treatment failure in Chagas patients reaching 70% to 90%, as opposed to 6% to 30% failure for benznidazole-treated patients. The lack of translation from in vitro and in vivo models to the clinic observed for the azoles raises several questions. There is a scientific requirement to review and challenge whether we are indeed using the right tools and decision-making processes to progress compounds forward for the treatment of this disease. New developments in the Chagas field, including new technologies and tools now available, will be discussed, and a redesign of the current screening strategy during the discovery process is proposed.
Collapse
Affiliation(s)
- Eric Chatelain
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| |
Collapse
|
217
|
Blaazer AR, Orrling KM, Shanmugham A, Jansen C, Maes L, Edink E, Sterk GJ, Siderius M, England P, Bailey D, de Esch IJP, Leurs R. Fragment-Based Screening in Tandem with Phenotypic Screening Provides Novel Antiparasitic Hits. ACTA ACUST UNITED AC 2014; 20:131-40. [DOI: 10.1177/1087057114549735] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Methods to discover biologically active small molecules include target-based and phenotypic screening approaches. One of the main difficulties in drug discovery is elucidating and exploiting the relationship between drug activity at the protein target and disease modification, a phenotypic endpoint. Fragment-based drug discovery is a target-based approach that typically involves the screening of a relatively small number of fragment-like (molecular weight <300) molecules that efficiently cover chemical space. Here, we report a fragment screening on TbrPDEB1, an essential cyclic nucleotide phosphodiesterase (PDE) from Trypanosoma brucei, and human PDE4D, an off-target, in a workflow in which fragment hits and a series of close analogs are subsequently screened for antiparasitic activity in a phenotypic panel. The phenotypic panel contained T. brucei, Trypanosoma cruzi, Leishmania infantum, and Plasmodium falciparum, the causative agents of human African trypanosomiasis (sleeping sickness), Chagas disease, leishmaniasis, and malaria, respectively, as well as MRC-5 human lung cells. This hybrid screening workflow has resulted in the discovery of various benzhydryl ethers with antiprotozoal activity and low toxicity, representing interesting starting points for further antiparasitic optimization.
Collapse
Affiliation(s)
- Antoni R. Blaazer
- Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), VU University Amsterdam, Amsterdam, The Netherlands
| | - Kristina M. Orrling
- Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), VU University Amsterdam, Amsterdam, The Netherlands
- TI Pharma, Leiden, The Netherlands
| | | | - Chimed Jansen
- Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), VU University Amsterdam, Amsterdam, The Netherlands
- University of Dundee, Dundee, UK
| | - Louis Maes
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Belgium
| | - Ewald Edink
- Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), VU University Amsterdam, Amsterdam, The Netherlands
| | - Geert Jan Sterk
- Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), VU University Amsterdam, Amsterdam, The Netherlands
| | - Marco Siderius
- Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), VU University Amsterdam, Amsterdam, The Netherlands
| | | | | | - Iwan J. P. de Esch
- Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), VU University Amsterdam, Amsterdam, The Netherlands
| | - Rob Leurs
- Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), VU University Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
218
|
Zingales B, Miles MA, Moraes CB, Luquetti A, Guhl F, Schijman AG, Ribeiro I. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz 2014; 109:828-33. [PMID: 25317712 PMCID: PMC4238778 DOI: 10.1590/0074-0276140156] [Citation(s) in RCA: 101] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Accepted: 06/27/2014] [Indexed: 11/22/2022] Open
Abstract
This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
Collapse
Affiliation(s)
- Bianca Zingales
- Instituto de Química, Universidade de São Paulo, São Paulo, SP,
Brasil
| | - Michael A Miles
- Faculty of Infectious and Tropical Diseases, London School of Hygiene
and Tropical Medicine, London, UK
| | - Carolina B Moraes
- Laboratório Nacional de Biociências, Centro Nacional de Pesquisa em
Energias e Matérias, Campinas, SP, Brasil
| | - Alejandro Luquetti
- Hospital das Clínicas, Universidade Federal de Goiás, Goiânia, GO,
Brasil
| | - Felipe Guhl
- Centro de Investigaciones en Microbiología y Parasitología Tropical,
Facultad de Ciencias, Universidad de los Andes, Bogotá,
Colombia
| | - Alejandro G Schijman
- Instituto de Investigaciones en Ingeniería Genética y Biología
Molecular-Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires,
Argentina
| | | |
Collapse
|
219
|
Oh S, Kim S, Kong S, Yang G, Lee N, Han D, Goo J, Siqueira-Neto JL, Freitas-Junior LH, Song R. Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi. Eur J Med Chem 2014; 84:395-403. [DOI: 10.1016/j.ejmech.2014.07.038] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2013] [Revised: 07/09/2014] [Accepted: 07/10/2014] [Indexed: 10/25/2022]
|
220
|
Cazorla SI, Matos MN, Cerny N, Ramirez C, Alberti AS, Bivona AE, Morales C, Guzmán CA, Malchiodi EL. Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis. J Infect Dis 2014; 211:698-707. [PMID: 25160983 DOI: 10.1093/infdis/jiu480] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
We have reported that attenuated Salmonella (S) carrying plasmids encoding the cysteine protease cruzipain (Cz) protects against Trypanosoma cruzi infection. Here, we determined whether immunoprotection could be improved by the oral coadministration of 3 Salmonella carrying the plasmids that encode the antigens Cz, Tc52, and Tc24. SCz+STc52+STc24-immunized mice presented an increased antibody response against each antigen compared with those in the single antigen-immunized groups, as well as higher trypomastigotes antibody-mediated lyses and cell invasion inhibition compared with controls. SCz+STc52+STc24-immunized and -challenged mice rendered lower parasitemia. Weight loss after infection was detected in all mice except those in the SCz+STc52+STc24 group. Moreover, cardiomyopathy-associated enzyme activity was significantly lower in SCz+STc24+STc52-immunized mice compared with controls. Few or no abnormalities were found in muscle tissues of SCz+STc24+STc52-immunized mice, whereas controls presented with inflammatory foci, necrosis, and amastigote nests. We conclude that a multicomponent approach that targets several invasion and metabolic mechanisms improves protection compared with single-component vaccines.
Collapse
Affiliation(s)
- Silvia I Cazorla
- Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral Dr. R. A. Margni, Consejo Nacional de Investigaciones Científicas y Técnicas-Universidad de Buenos Aires (CONICET-UBA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Instituto de Microbiología y Parasitología Médica (IMPaM), UBA-CONICET and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, UBA
| | - Marina N Matos
- Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral Dr. R. A. Margni, Consejo Nacional de Investigaciones Científicas y Técnicas-Universidad de Buenos Aires (CONICET-UBA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Instituto de Microbiología y Parasitología Médica (IMPaM), UBA-CONICET and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, UBA
| | - Natacha Cerny
- Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral Dr. R. A. Margni, Consejo Nacional de Investigaciones Científicas y Técnicas-Universidad de Buenos Aires (CONICET-UBA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Instituto de Microbiología y Parasitología Médica (IMPaM), UBA-CONICET and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, UBA
| | - Carolina Ramirez
- Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral Dr. R. A. Margni, Consejo Nacional de Investigaciones Científicas y Técnicas-Universidad de Buenos Aires (CONICET-UBA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Instituto de Microbiología y Parasitología Médica (IMPaM), UBA-CONICET and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, UBA
| | - Andrés Sanchez Alberti
- Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral Dr. R. A. Margni, Consejo Nacional de Investigaciones Científicas y Técnicas-Universidad de Buenos Aires (CONICET-UBA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Instituto de Microbiología y Parasitología Médica (IMPaM), UBA-CONICET and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, UBA
| | - Augusto E Bivona
- Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral Dr. R. A. Margni, Consejo Nacional de Investigaciones Científicas y Técnicas-Universidad de Buenos Aires (CONICET-UBA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Instituto de Microbiología y Parasitología Médica (IMPaM), UBA-CONICET and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, UBA
| | - Celina Morales
- Departamento de Patología, Facultad de Medicina UBA, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina
| | - Carlos A Guzmán
- Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
| | - Emilio L Malchiodi
- Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral Dr. R. A. Margni, Consejo Nacional de Investigaciones Científicas y Técnicas-Universidad de Buenos Aires (CONICET-UBA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Instituto de Microbiología y Parasitología Médica (IMPaM), UBA-CONICET and Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, UBA
| |
Collapse
|
221
|
Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge. Infect Immun 2014; 82:4265-75. [PMID: 25069980 DOI: 10.1128/iai.02190-14] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
In this work we immunized mice with DNA encoding full-length Tc52 or its amino- or carboxy-terminal (N- and C-term, respectively) domain carried by attenuated Salmonella as a DNA delivery system. As expected, Salmonella-mediated DNA delivery resulted in low antibody titers and a predominantly Th1 response, as shown by the ratio of IgG2a/IgG1-specific antibodies. Despite modest expression of Tc52 in trypomastigotes, the antibodies elicited by vaccination were able to mediate lysis of the trypomastigotes in the presence of complement and inhibit their invasion of mammal cells in vitro. The strongest functional activity was observed with sera from mice immunized with Salmonella carrying the N-term domain (SN-term), followed by Tc52 (STc52), and the C-term domain (SC-term). All immunized groups developed strong cellular responses, with predominant activation of Th1 cells. However, mice immunized with SN-term showed higher levels of interleukin-10 (IL-10), counterbalancing the inflammatory reaction, and also strong activation of Tc52-specific gamma interferon-positive (IFN-γ(+)) CD8(+) T cells. In agreement with this, although all prototypes conferred protection against infection, immunization with SN-term promoted greater protection than that with SC-term for all parameters tested and slightly better protection than that with STc52, especially in the acute stage of infection. We conclude that the N-terminal domain of Tc52 is the section of the protein that confers maximal protection against infection and propose it as a promising candidate for vaccine development.
Collapse
|
222
|
Planer JD, Hulverson MA, Arif JA, Ranade RM, Don R, Buckner FS. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl Trop Dis 2014; 8:e2977. [PMID: 25033456 PMCID: PMC4102417 DOI: 10.1371/journal.pntd.0002977] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Accepted: 05/12/2014] [Indexed: 12/14/2022] Open
Abstract
An estimated 8 million persons, mainly in Latin America, are infected with Trypanosoma cruzi, the etiologic agent of Chagas disease. Existing antiparasitic drugs for Chagas disease have significant toxicities and suboptimal effectiveness, hence new therapeutic strategies need to be devised to address this neglected tropical disease. Due to the high research and development costs of bringing new chemical entities to the clinic, we and others have investigated the strategy of repurposing existing drugs for Chagas disease. Screens of FDA-approved drugs (described in this paper) have revealed a variety of chemical classes that have growth inhibitory activity against mammalian stage Trypanosoma cruzi parasites. Aside from azole antifungal drugs that have low or sub-nanomolar activity, most of the active compounds revealed in these screens have effective concentrations causing 50% inhibition (EC50's) in the low micromolar or high nanomolar range. For example, we have identified an antihistamine (clemastine, EC50 of 0.4 µM), a selective serotonin reuptake inhibitor (fluoxetine, EC50 of 4.4 µM), and an antifolate drug (pyrimethamine, EC50 of 3.8 µM) and others. When tested alone in the murine model of Trypanosoma cruzi infection, most compounds had insufficient efficacy to lower parasitemia thus we investigated using combinations of compounds for additive or synergistic activity. Twenty-four active compounds were screened in vitro in all possible combinations. Follow up isobologram studies showed at least 8 drug pairs to have synergistic activity on T. cruzi growth. The combination of the calcium channel blocker, amlodipine, plus the antifungal drug, posaconazole, was found to be more effective at lowering parasitemia in mice than either drug alone, as was the combination of clemastine and posaconazole. Using combinations of FDA-approved drugs is a promising strategy for developing new treatments for Chagas disease. Chronic infection with Trypanosoma cruzi causes progressive damage to the heart and other organs that is fatal in about 30% of cases. Known as Chagas disease, this is a major public health problem in Latin America. The existing medicines were developed over forty years ago and are not widely used because of toxicity and unreliable effectiveness. To discover better treatments, we screened a collection of existing drugs for growth inhibitory activity on Trypanosoma cruzi. Several dozen orally administered drugs were discovered, but when used by themselves they were not strong enough to cure the infection in an animal model. We tested a set of 24 of these drugs in every two-way combination and identified eight synergistic partners. At least two of these combinations were able to substantially lower parasite levels in the mouse model of Trypanosoma cruzi infection. Thus, finding pairs of FDA-approved drugs that can be used in combination may be a pragmatic and effective strategy for designing new therapies for Chagas disease.
Collapse
Affiliation(s)
- Joseph D. Planer
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Matthew A. Hulverson
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Jennifer A. Arif
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Ranae M. Ranade
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Robert Don
- Drugs for Neglected Diseases Initiative, Geneva, Switzerland
| | - Frederick S. Buckner
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
- * E-mail:
| |
Collapse
|
223
|
Ferrins L, Gazdik M, Rahmani R, Varghese S, Sykes ML, Jones AJ, Avery VM, White KL, Ryan E, Charman SA, Kaiser M, Bergström CAS, Baell JB. Pyridyl Benzamides as a Novel Class of Potent Inhibitors for the Kinetoplastid Trypanosoma brucei. J Med Chem 2014; 57:6393-402. [DOI: 10.1021/jm500191u] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
| | - Michelle Gazdik
- Department
of Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia
- The Walter and Eliza Hall Institute, 1G Royal Parade, Parkville, Victoria 3052, Australia
| | | | - Swapna Varghese
- Department
of Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia
| | - Melissa L. Sykes
- Eskitis
Institute
for Drug Discovery, Griffith University, Brisbane Innovation Park, Don Young
Road, Nathan, Queensland 4111, Australia
| | - Amy J. Jones
- Eskitis
Institute
for Drug Discovery, Griffith University, Brisbane Innovation Park, Don Young
Road, Nathan, Queensland 4111, Australia
| | - Vicky M. Avery
- Eskitis
Institute
for Drug Discovery, Griffith University, Brisbane Innovation Park, Don Young
Road, Nathan, Queensland 4111, Australia
| | | | | | | | - Marcel Kaiser
- Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel, 4051, Switzerland
- University of Basel, Petersplatz
1, Basel, 4003, Switzerland
| | - Christel A. S. Bergström
- Department
of Pharmacy, Uppsala University, Biomedical Center P.O. Box 580, SE-751
23 Uppsala, Sweden
| | - Jonathan B. Baell
- The Walter and Eliza Hall Institute, 1G Royal Parade, Parkville, Victoria 3052, Australia
- Department
of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
| |
Collapse
|
224
|
LIMA LUCIANAA, ALVES TÂNIAM, ZANI CARLOSL, SALES JÚNIOR POLICARPOA, ROMANHA ALVAROJ, JOHANN SUSANA, CISALPINO PATRÍCIAS, PIMENTA LÚCIAP, BOAVENTURA MARIAAMÉLIAD. In vitro cytotoxic, antifungal, trypanocidal and leishmanicidal activities of acetogenins isolated from Annona cornifolia A. St. -Hil. (Annonaceae). AN ACAD BRAS CIENC 2014. [DOI: 10.1590/0001-3765201420130048] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Annona cornifolia A. St. -Hil. is a small annual perennial tree found in the Brazilian savannah; their green fruit is popularly used in the treatment of ulcers. The acetogenins isolated from the seeds of Annona cornifolia previously showed to possess antioxidant activity. In continuation of our investigations on the biological activities of acetogenins, four binary mixtures and ten pure adjacent bis-tetrahydrofuran annonaceous acetogenins were evaluated: the cytotoxic (against three human tumor cell lines), antifungal (against Paracoccidioides brasiliensis), trypanocidal (against Trypanosoma cruzi) and leishmanicidal (against Leishmania amazonensis) activities. Acetogenins presented cytotoxic activity confirming their potential use in anti-cancer therapy. Regarding leishmanicidal and trypanocidal activities, an inhibition of 87% of L. amazonensis amastigotes and 100% of T. cruzi amastigotes and trypomastigotes was observed, when tested at the concentration of 20 µg mL–1. Moreover, six acetogenins showed more activity against all the three tested isolates of P. brasiliensis than trimethoprim-sulfamethoxazole, a drug used for treating paracoccidioidomycosis. Thus, acetogenins may be an alternative in treating a number of diseases that have a huge impact on millions of people worldwide. This paper reports for the first time the antifungal, leishmanicidal and trypanocidal activities for these acetogenins.
Collapse
|
225
|
Evaluation of the in vitro antiplasmodial, antileishmanial, and antitrypanosomal activity of medicinal plants used in saudi and yemeni traditional medicine. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2014; 2014:905639. [PMID: 24963330 PMCID: PMC4055400 DOI: 10.1155/2014/905639] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/28/2014] [Accepted: 04/30/2014] [Indexed: 11/17/2022]
Abstract
The antiplasmodial, antileishmanial, and antitrypanosomal activity of twenty-five medicinal plants distributed in Saudi Arabia and Yemen was evaluated. The plants were extracted with methanol and screened in vitro against erythrocytic schizonts of Plasmodium falciparum, intracellular amastigotes of Leishmania infantum and Trypanosoma cruzi, and free trypomastigotes of T. brucei. To assess selectivity, cytotoxicity was determined on MRC-5 cells. Criteria for activity were an IC50 < 10 μg/mL and high selectivity (SI). Seven plants showed interesting antiprotozoal activity in one or more models. Extracts of Caralluma penicillata and Acalypha ciliata showed fairly good activity against P. falciparum with IC50 of 6.7 and 10.8 μg/mL and adequate selectivity (SI > 9.6 and >5.9). Interesting activity against L. infantum was obtained with Verbascum bottae (IC50 of 3.2 μg/mL, SI 10.2) and Solanum glabratum (IC50 8.1 μg/mL, SI 3.4). The extracts of C. penicillata, Leucas virgata, Loranthus regularis, and V. bottae exhibited moderate activity against T. brucei (IC50 8.5, 8.1, 8.3, and 2.3 μg/mL; SI > 7.6, 7.7, 4.3, and >14.1). These results partly support the traditional use of some of the selected medicinal plants and warrant further investigations into the putative active constituents.
Collapse
|
226
|
Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi. Future Med Chem 2014; 5:1733-52. [PMID: 24144410 DOI: 10.4155/fmc.13.139] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Inhibitors of Trypanosoma cruzi with novel mechanisms of action are urgently required to diversify the current clinical and preclinical pipelines. Increasing the number and diversity of hits available for assessment at the beginning of the discovery process will help to achieve this aim. RESULTS We report the evaluation of multiple hits generated from a high-throughput screen to identify inhibitors of T. cruzi and from these studies the discovery of two novel series currently in lead optimization. Lead compounds from these series potently and selectively inhibit growth of T. cruzi in vitro and the most advanced compound is orally active in a subchronic mouse model of T. cruzi infection. CONCLUSION High-throughput screening of novel compound collections has an important role to play in diversifying the trypanosomatid drug discovery portfolio. A new T. cruzi inhibitor series with good drug-like properties and promising in vivo efficacy has been identified through this process.
Collapse
|
227
|
In vitro antiprotozoal activity of abietane diterpenoids isolated from Plectranthus barbatus Andr. Int J Mol Sci 2014; 15:8360-71. [PMID: 24823881 PMCID: PMC4057736 DOI: 10.3390/ijms15058360] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Revised: 04/24/2014] [Accepted: 05/06/2014] [Indexed: 11/17/2022] Open
Abstract
Chromatographic separation of the n-hexane extract of the aerial part of Plectranthus barbatus led to the isolation of five abietane-type diterpenes: dehydroabietane (1); 5,6-didehydro-7-hydroxy-taxodone (2); taxodione (3); 20-deoxocarnosol (4) and 6α,11,12,-trihydroxy-7β,20-epoxy-8,11,13-abietatriene (5). The structures were determined using spectroscopic methods including one- and two-dimensional NMR methods. Compounds (1)–(3) and (5) are isolated here for the first time from the genus Plectranthus. The isolated abietane-type diterpenes tested in vitro for their antiprotozoal activity against erythrocytic schizonts of Plasmodium falciparum, intracellular amastigotes of Leishmania infantum and Trypanosoma cruzi and free trypomastigotes of T. brucei. Cytotoxicity was determined against fibroblast cell line MRC-5. Compound (2) 5,6-didehydro-7-hydroxy-taxodone showed remarkable activity with acceptable selectivity against P. falciparum (IC50 9.2 μM, SI 10.4) and T. brucei (IC50 1.9 μM, SI 50.5). Compounds (3)–(5) exhibited non-specific antiprotozoal activity due to high cytotoxicity. Compound (1) dehydroabietane showed no antiprotozoal potential.
Collapse
|
228
|
New drugs with antiprotozoal activity from marine algae: a review. REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY 2014. [DOI: 10.1016/j.bjp.2014.07.001] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
229
|
Sales Júnior PA, Rezende Júnior CO, Le Hyaric M, Almeida MVD, Romanha AJ. The in vitro activity of fatty diamines and amino alcohols against mixed amastigote and trypomastigote Trypanosoma cruzi forms. Mem Inst Oswaldo Cruz 2014; 109:362-4. [PMID: 24831550 PMCID: PMC4131791 DOI: 10.1590/0074-0276130496] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Accepted: 12/03/2013] [Indexed: 11/22/2022] Open
Abstract
Four diamines and three amino alcohols derived from 1-decanol, 1-dodecanol and
1,2-dodecanediol were evaluated in an in vitro assay against a mixture of
trypomastigote and intracellular amastigote forms of Trypanosoma
cruzi. Two of these compounds (6 and 7) showed better activity against
both proliferative stages of T. cruzi than the positive control
benznidazole, three were of similar potency (1, 2 and 5) and two were less active (3
and 4).
Collapse
Affiliation(s)
- Policarpo Ademar Sales Júnior
- Laboratório de Parasitologia Celular e Molecular, Centro de Pesquisas René Rachou-Fiocruz, Belo Horizonte, MG, Brasil
| | | | - Mireille Le Hyaric
- Departamento de Química, Universidade Federal de Juiz de Fora, Juiz de Fora,, MG, Brasil
| | | | - Alvaro José Romanha
- Laboratório de Parasitologia Celular e Molecular, Centro de Pesquisas René Rachou-Fiocruz, Belo Horizonte, MG, Brasil
| |
Collapse
|
230
|
Abstract
Chagas' disease is a neglected tropical disease caused by Trypanosoma cruzi and constitutes a serious public health problem for Latin America. Its unsatisfactory chemotherapy stimulates the search for novel antiparasitic compounds. Amidines and related compounds exhibit well-known activity towards different microbes including T. cruzi. In this vein, our present aim was to evaluate the biological effect of 10 novel structurally related amidines in vitro against bloodstream and intracellular forms of the parasite as well as their potential toxicity on cardiac cell cultures. Our results show that although active against the extracellular forms, with some of them like DB2247 being 6-fold more effective than benznidazole and displaying very low toxicity (>96 μm), none presented superior trypanocidal effect against intracellular forms as compared with the reference drug. These results may be due to differences in susceptibility profiles related to distinct uptake/extrusion mechanisms and cellular targets between bloodstream and amastigote forms. The present study adds to the knowledge base for the future design of novel amidines that may provide promising activity against T. cruzi.
Collapse
|
231
|
PrestoBlue® and AlamarBlue® are equally useful as agents to determine the viability of Acanthamoeba trophozoites. Exp Parasitol 2014; 145 Suppl:S69-72. [PMID: 24703973 DOI: 10.1016/j.exppara.2014.03.024] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2013] [Revised: 03/19/2014] [Accepted: 03/23/2014] [Indexed: 11/23/2022]
Abstract
Acanthamoeba is an opportunistic pathogen which is the causal agent of several human infections such as Granulomatous Amoebic Encephalitis, Acanthamoeba keratitis and other disseminated infections. Furthermore, current therapeutic measures against Acanthamoeba infections are arduous, and show limited efficacy against the cyst stage of Acanthamoeba. There is a pressing need to search and evaluate new therapeutic agents against these protozoa. Our approach for evaluating possible new drugs is an initial in vitro screening assay based on general metabolic activity of the cells. In this study we compare two agents, AlamarBlue® and PrestoBlue® for this initial screen. Both reagents can be used to indicate metabolism by changes in their absorbance or fluorescence. The assay is carried out in a 96-well plate format and fluorescence can be measured after an inoculation period of as little as 10 min, but more typically 96 h. This to the best of our knowledge this is the first time that both compounds are directly compared using absorbance and fluorescence measurement. We conclude that for the specific case of Acanthamoeba both agents AlamarBlue® and PrestoBlue® are equally useful to determine cell viability.
Collapse
|
232
|
Fügi MA, Gunasekera K, Ochsenreiter T, Guan X, Wenk MR, Mäser P. Genome profiling of sterol synthesis shows convergent evolution in parasites and guides chemotherapeutic attack. J Lipid Res 2014; 55:929-38. [PMID: 24627128 DOI: 10.1194/jlr.m048017] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Sterols are an essential class of lipids in eukaryotes, where they serve as structural components of membranes and play important roles as signaling molecules. Sterols are also of high pharmacological significance: cholesterol-lowering drugs are blockbusters in human health, and inhibitors of ergosterol biosynthesis are widely used as antifungals. Inhibitors of ergosterol synthesis are also being developed for Chagas's disease, caused by Trypanosoma cruzi. Here we develop an in silico pipeline to globally evaluate sterol metabolism and perform comparative genomics. We generate a library of hidden Markov model-based profiles for 42 sterol biosynthetic enzymes, which allows expressing the genomic makeup of a given species as a numerical vector. Hierarchical clustering of these vectors functionally groups eukaryote proteomes and reveals convergent evolution, in particular metabolic reduction in obligate endoparasites. We experimentally explore sterol metabolism by testing a set of sterol biosynthesis inhibitors against trypanosomatids, Plasmodium falciparum, Giardia, and mammalian cells, and by quantifying the expression levels of sterol biosynthetic genes during the different life stages of T. cruzi and Trypanosoma brucei. The phenotypic data correlate with genomic makeup for simvastatin, which showed activity against trypanosomatids. Other findings, such as the activity of terbinafine against Giardia, are not in agreement with the genotypic profile.
Collapse
Affiliation(s)
- Matthias A Fügi
- Swiss Tropical and Public Health Institute, Basel, Switzerland
| | | | | | | | | | | |
Collapse
|
233
|
Ferreira RS, Dessoy MA, Pauli I, Souza ML, Krogh R, Sales AIL, Oliva G, Dias LC, Andricopulo AD. Synthesis, biological evaluation, and structure-activity relationships of potent noncovalent and nonpeptidic cruzain inhibitors as anti-Trypanosoma cruzi agents. J Med Chem 2014; 57:2380-92. [PMID: 24533839 DOI: 10.1021/jm401709b] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The development of cruzain inhibitors has been driven by the urgent need to develop novel and more effective drugs for the treatment of Chagas' disease. Herein, we report the lead optimization of a class of noncovalent cruzain inhibitors, starting from an inhibitor previously cocrystallized with the enzyme (K(i) = 0.8 μM). With the goal of achieving a better understanding of the structure-activity relationships, we have synthesized and evaluated a series of over 40 analogues, leading to the development of a very promising competitive inhibitor (8r, IC50 = 200 nM, K(i) = 82 nM). Investigation of the in vitro trypanocidal activity and preliminary cytotoxicity revealed the potential of the most potent cruzain inhibitors in guiding further medicinal chemistry efforts to develop drug candidates for Chagas' disease.
Collapse
Affiliation(s)
- Rafaela S Ferreira
- Laboratório de Química Medicinal e Computacional, Centro de Pesquisa e Inovação em Biodiversidade e Fármacos, Instituto de Física de São Carlos, Universidade de São Paulo , Avenida João Dagnone 1100, Jardim Santa Angelina, São Carlos, SP 13563-120, Brazil
| | | | | | | | | | | | | | | | | |
Collapse
|
234
|
Fonseca-Berzal C, Escario JA, Arán VJ, Gómez-Barrio A. Further insights into biological evaluation of new anti-Trypanosoma cruzi 5-nitroindazoles. Parasitol Res 2014; 113:1049-56. [PMID: 24435615 DOI: 10.1007/s00436-013-3740-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Accepted: 12/23/2013] [Indexed: 11/25/2022]
Abstract
Twelve molecules from a series of 35 new 5-nitroindazole derivatives, selected from a successful primary screening on Trypanosoma cruzi epimastigotes, have been evaluated against intracellular amastigotes according to the previous results of their trypanocidal activity and unspecific cytotoxicity. 2-Benzyl-1-propyl (22), 2-benzyl-1-isopropyl (23), and 2-benzyl-1-butyl (24) 5-nitroindazolin-3-ones have inhibited the growth of amastigotes similarly to the reference drugs benznidazole and nifurtimox, inducing complete growth inhibition at concentrations lower than 8 μM (IC₅₀ < 5 μM) and accomplishing great selectivity indexes on the intracellular form of the parasite (SI > 30). Further in vivo assays were developed only for two of the most active molecules (22 and 24), reaching significant reductions in parasitemia levels (52 % and 77%, respectively) after their oral administration to infected mice. In addition, none of the mice in experimental and benznidazole groups died, unlike in the control group which is only treated with the vehicle. The trypanocidal properties found in some of the 5-nitroindazole derivatives assayed in the present work represent an interesting contribution to the urgent need for searching new antichagasic drugs.
Collapse
Affiliation(s)
- Cristina Fonseca-Berzal
- Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid (CEI Campus Moncloa, UCM-UPM & CSIC), Pza. Ramón y Cajal s/n, 28040, Madrid, Spain,
| | | | | | | |
Collapse
|
235
|
Essential oil from Chenopodium ambrosioides and main components: Activity against Leishmania, their mitochondria and other microorganisms. Exp Parasitol 2014; 136:20-6. [DOI: 10.1016/j.exppara.2013.10.007] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2013] [Revised: 09/11/2013] [Accepted: 10/23/2013] [Indexed: 11/21/2022]
|
236
|
Keenan M, Chaplin JH, Alexander PW, Abbott MJ, Best WM, Khong A, Botero A, Perez C, Cornwall S, Thompson RA, White KL, Shackleford DM, Koltun M, Chiu FCK, Morizzi J, Ryan E, Campbell M, von Geldern TW, Scandale I, Chatelain E, Charman SA. Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. J Med Chem 2013; 56:10158-70. [PMID: 24304150 PMCID: PMC3884847 DOI: 10.1021/jm401610c] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
![]()
Chagas
disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is an increasing threat to global health.
Available medicines were introduced over 40 years ago, have undesirable
side effects, and give equivocal results of cure in the chronic stage
of the disease. We report the development of two compounds, 6 and (S)-7, with PCR-confirmed
curative activity in a mouse model of established T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7. Compounds 6 and (S)-7 have potent in vitro activity, are noncytotoxic,
show no adverse effects in vivo following repeat dosing, are prepared
by a short synthetic route, and have druglike properties suitable
for preclinical development.
Collapse
Affiliation(s)
- Martine Keenan
- Epichem Pty Ltd. , Murdoch University Campus, South Street, Murdoch, Western Australia 6150, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
237
|
Suryadevara PK, Racherla KK, Olepu S, Norcross NR, Tatipaka HB, Arif JA, Planer JD, Lepesheva G, Verlinde CLMJ, Buckner FS, Gelb MH. Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents. Bioorg Med Chem Lett 2013; 23:6492-9. [PMID: 24120539 PMCID: PMC4111244 DOI: 10.1016/j.bmcl.2013.08.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2013] [Revised: 07/24/2013] [Accepted: 08/05/2013] [Indexed: 11/29/2022]
Abstract
New dialkylimidazole based sterol 14α-demethylase inhibitors were prepared and tested as potential anti-Trypanosoma cruzi agents. Previous studies had identified compound 2 as the most potent and selective inhibitor against parasite cultures. In addition, animal studies had demonstrated that compound 2 is highly efficacious in the acute model of the disease. However, compound 2 has a high molecular weight and high hydrophobicity, issues addressed here. Systematic modifications were carried out at four positions on the scaffold and several inhibitors were identified which are highly potent (EC50 <1 nM) against T. cruzi in culture. The halogenated derivatives 36j, 36k, and 36p, display excellent activity against T. cruzi amastigotes, with reduced molecular weight and lipophilicity, and exhibit suitable physicochemical properties for an oral drug candidate.
Collapse
Affiliation(s)
| | | | - Srinivas Olepu
- Department of Chemistry, University of Washington, Seattle, Washington 98195, USA
| | - Neil R. Norcross
- Department of Chemistry, University of Washington, Seattle, Washington 98195, USA
| | - Hari Babu Tatipaka
- Department of Chemistry, University of Washington, Seattle, Washington 98195, USA
| | - Jennifer A. Arif
- Medicine, University of Washington, Seattle, Washington 98195, USA
| | - Joseph D. Planer
- Medicine, University of Washington, Seattle, Washington 98195, USA
| | - Galina Lepesheva
- Department of Biochemistry, School of Medicine, Vanderbilt University, Nashville, TN, USA
| | | | | | - Michael H. Gelb
- Department of Chemistry, University of Washington, Seattle, Washington 98195, USA
| |
Collapse
|
238
|
Faral-Tello P, Liang M, Mahler G, Wipf P, Robello C. Imidazolium compounds are active against all stages of Trypanosoma cruzi. Int J Antimicrob Agents 2013; 43:262-8. [PMID: 24359836 DOI: 10.1016/j.ijantimicag.2013.10.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2013] [Revised: 10/17/2013] [Accepted: 10/21/2013] [Indexed: 11/17/2022]
Abstract
Imidazolium salts are best known for their applications in organic synthesis as room-temperature ionic liquids, or as precursors of stable carbenes, but they also show important biological properties such as anti-oxidative effects, induction of mitochondrial membrane permeabilisation and inhibition of the infection cycle of Plasmodium falciparum. For these reasons, and since chemotherapy for Chagas disease is inefficient, the aim of this study was to test the use of imidazolium compounds against the kinetoplastid haemoflagellate aetiological agent for this disease, namely Trypanosoma cruzi. The results show that five of the tested compounds are more effective than the reference drug benznidazole against the epimastigote and trypomastigote forms of T. cruzi. Moreover, intracellular amastigotes were also affected by the compounds, which showed lower toxicity in host cells. Transmission electron microscopy analysis demonstrated that the tested agents induced alterations of the kinetoplast and particularly of the mitochondria, leading to extraordinary swelling of the organelle. These results further demonstrate that the test agents with the best profile are those bearing symmetrical bulky substituents at N(1) and N(3), displaying promising activity against all forms of T. cruzi, interesting selectivity indexes and exceptional activity at low doses. Accordingly, these agents represent promising candidates for the treatment of Chagas disease.
Collapse
Affiliation(s)
- Paula Faral-Tello
- Unidad de Biología Molecular, Institut Pasteur de Montevideo, Mataojo 2020, Montevideo, Uruguay
| | - Mary Liang
- Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Graciela Mahler
- Cátedra de Química Farmacéutica, DQO, Facultad de Química, Universidad de la República, Avenida General Flores 2124, Montevideo, Uruguay
| | - Peter Wipf
- Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Carlos Robello
- Unidad de Biología Molecular, Institut Pasteur de Montevideo, Mataojo 2020, Montevideo, Uruguay; Departamento de Bioquímica, Facultad de Medicina, Universidad de la República, Avenida General Flores 2425, Montevideo, Uruguay.
| |
Collapse
|
239
|
Braga SFP, Alves ÉVP, Ferreira RS, Fradico JRB, Lage PS, Duarte MC, Ribeiro TG, Júnior PAS, Romanha AJ, Tonini ML, Steindel M, Coelho EF, de Oliveira RB. Synthesis and evaluation of the antiparasitic activity of bis-(arylmethylidene) cycloalkanones. Eur J Med Chem 2013; 71:282-9. [PMID: 24321832 DOI: 10.1016/j.ejmech.2013.11.011] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2013] [Revised: 11/02/2013] [Accepted: 11/07/2013] [Indexed: 11/27/2022]
Abstract
A series of bis-(arylmethylidene)-cycloalkanones was synthesized by cross-aldol condensation. The activity of the compounds was evaluated against amastigotes forms of Trypanosoma cruzi and promastigotes forms of Leishmania amazonensis. The cytotoxicity of the active compounds on uninfected fibroblasts or macrophages was established in vitro to evaluate the selectivity of their antiparasitic effects. Six compounds displayed trypanocidal activity against amastigotes intracellular forms of T. cruzi with IC₅₀ values ranging from 7.0 to 249 μM. Besides these six compounds, eight other molecules exhibited significant leishmanicidal activity (IC₅₀ values ranging from 0.6 to 110.4 μM). Two compounds can be considered as promising antiparasitic lead molecules because they showed IC₅₀ values in the low-micromolar range (≤1.2 μM) with an adequate SI (≥19.9). To understand the mechanism of action of these compounds, two possible molecular targets were investigated: trypanothione reductase (TR) and cruzain.
Collapse
Affiliation(s)
- Saulo F P Braga
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Belo Horizonte 31.270-901, MG, Brazil
| | - Érika V P Alves
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Belo Horizonte 31.270-901, MG, Brazil
| | - Rafaela S Ferreira
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Belo Horizonte 31.270-901, MG, Brazil
| | - Jordana R B Fradico
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Belo Horizonte 31.270-901, MG, Brazil
| | - Paula S Lage
- Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Mariana C Duarte
- Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Tatiana G Ribeiro
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Belo Horizonte 31.270-901, MG, Brazil
| | - Policarpo A S Júnior
- Centro de Pesquisas René Rachou, FIOCRUZ, Avenida Augusto de Lima, 1.715, Barro Preto, Belo Horizonte 30.190-002, MG, Brazil
| | - Alvaro J Romanha
- Centro de Pesquisas René Rachou, FIOCRUZ, Avenida Augusto de Lima, 1.715, Barro Preto, Belo Horizonte 30.190-002, MG, Brazil
| | - Maiko L Tonini
- Departamento de Microbiologia, Imunologia e Parasitologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Setor F, Bloco A, Florianópolis 88.040-970, SC, Brazil
| | - Mário Steindel
- Departamento de Microbiologia, Imunologia e Parasitologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Setor F, Bloco A, Florianópolis 88.040-970, SC, Brazil
| | - Eduardo F Coelho
- Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Renata B de Oliveira
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, Belo Horizonte 31.270-901, MG, Brazil.
| |
Collapse
|
240
|
Clark KE, Capper A, Togna GD, Paul VJ, Romero LI, Johns T, Cubilla-Rios L, Capson TL. Ecology- and Bioassay-Guided Drug Discovery for Treatments of Tropical Parasitic Disease: 5α,8α-Epidioxycholest-6-en-3β-ol Isolated from the Mollusk Dolabrifera dolabrifera Shows Significant Activity against Leishmania donovani. Nat Prod Commun 2013. [DOI: 10.1177/1934578x1300801109] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
An ecology- and bioassay-guided search employed to discover compounds with activity against tropical parasitic diseases and cancer from the opisthobranch mollusk, Dolabrifera dolabrifera, led to the discovery of antileishmanial properties in the known compound, 5α,8α-epidioxycholest-6-en-3β-ol (1). Compound 1 was identified through nuclear magnetic resonance spectroscopy (1H, 13C) and mass spectrometry. The compound was concentrated in the digestive gland of D. dolabrifera, but was not detected in other body parts, fecal matter or mucus. Compound 1 showed an IC50 of 4.9 μM towards the amastigote form of Leishmania donovani compared with an IC50 of 281 μM towards the control Vero cell line, a 57.3-fold difference, and demonstrated no measurable activity against Plasmodium falciparum, Trypanosoma cruzi, and the breast cancer cell line, MCF-7.
Collapse
Affiliation(s)
- Kathryn E. Clark
- Smithsonian Tropical Research Institute, Apartado 2072, Balboa Ancón, Republic of Panama
- Department of Plant Science, McGill University, 21,111 Lakeshore, Ste. Anne de Bellevue, Quebec H9X 3V9, Canada
- current address: Oxford University Centre for the Environment, South Parks Road, Oxford, OX1 3QY, UK
| | - Angela Capper
- Smithsonian Marine Station at Fort Pierce, 701 Seaway Drive, Fort Pierce, Florida 34949, USA
- current address: Centre for Sustainable Tropical Fisheries and Aquaculture & School of Marine and Tropical Biology, James Cook University, Townsville, QLD 4811, Australia
| | - Gina Della Togna
- Instituto de Investigaciones Científicas Avanzadas y Servicios de Alta Tecnología, Clayton, Edificio 175, PO Box 7250, Panama City, Republic of Panama
- current address: Center for Species Survival, Smithsonian Conservation Biology Institute, National Zoological Park, P.O. Box 37012, MRC 5502, Washington, DC 20013–7012, USA
| | - Valerie J. Paul
- Smithsonian Marine Station at Fort Pierce, 701 Seaway Drive, Fort Pierce, Florida 34949, USA
| | - Luz I. Romero
- Instituto de Investigaciones Científicas Avanzadas y Servicios de Alta Tecnología, Clayton, Edificio 175, PO Box 7250, Panama City, Republic of Panama
| | - Timothy Johns
- Department of Plant Science, McGill University, 21,111 Lakeshore, Ste. Anne de Bellevue, Quebec H9X 3V9, Canada
| | - Luis Cubilla-Rios
- Laboratorio de Bioorgánica Tropical, Departamento de Química Orgánica, Universidad de Panamá, Apartado 0824–10835, Panama City, Republic of Panama
| | - Todd L. Capson
- Smithsonian Tropical Research Institute, Apartado 2072, Balboa Ancón, Republic of Panama
- Department of Plant Science, McGill University, 21,111 Lakeshore, Ste. Anne de Bellevue, Quebec H9X 3V9, Canada
- current address: 1743 18th St. NW Washington DC, 20009 USA
| |
Collapse
|
241
|
Jones AJ, Grkovic T, Sykes ML, Avery VM. Trypanocidal activity of marine natural products. Mar Drugs 2013; 11:4058-82. [PMID: 24152565 PMCID: PMC3826150 DOI: 10.3390/md11104058] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Revised: 10/09/2013] [Accepted: 10/10/2013] [Indexed: 12/21/2022] Open
Abstract
Marine natural products are a diverse, unique collection of compounds with immense therapeutic potential. This has resulted in these molecules being evaluated for a number of different disease indications including the neglected protozoan diseases, human African trypanosomiasis and Chagas disease, for which very few drugs are currently available. This article will review the marine natural products for which activity against the kinetoplastid parasites; Trypanosoma brucei brucei, T.b. rhodesiense and T. cruzi has been reported. As it is important to know the selectivity of a compound when evaluating its trypanocidal activity, this article will only cover molecules which have simultaneously been tested for cytotoxicity against a mammalian cell line. Compounds have been grouped according to their chemical structure and representative examples from each class were selected for detailed discussion.
Collapse
Affiliation(s)
- Amy J Jones
- Eskitis Institute for Drug Discovery, Griffith University, Nathan, Brisbane 4111, Australia.
| | | | | | | |
Collapse
|
242
|
Sülsen VP, Cazorla SI, Frank FM, Laurella LC, Muschietti LV, Catalán CA, Martino VS, Malchiodi EL. Natural terpenoids from Ambrosia species are active in vitro and in vivo against human pathogenic trypanosomatids. PLoS Negl Trop Dis 2013; 7:e2494. [PMID: 24130916 PMCID: PMC3794960 DOI: 10.1371/journal.pntd.0002494] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Accepted: 09/09/2013] [Indexed: 11/18/2022] Open
Abstract
Among the natural compounds, terpenoids play an important role in the drug discovery process for tropical diseases. The aim of the present work was to isolate antiprotozoal compounds from Ambrosia elatior and A. scabra. The sesquiterpene lactone (STL) cumanin was isolated from A. elatior whereas two other STLs, psilostachyin and cordilin, and one sterol glycoside, daucosterol, were isolated from A. scabra. Cumanin and cordilin were active against Trypanosoma cruzi epimastigotes showing 50% inhibition concentrations (IC50) values of 12 µM and 26 µM, respectively. Moreover, these compounds are active against bloodstream trypomastigotes, regardless of the T. cruzi strain tested. Psilostachyin and cumanin were also active against amastigote forms with IC50 values of 21 µM and 8 µM, respectively. By contrast, daucosterol showed moderate activity on epimastigotes and trypomastigotes and was inactive against amastigote forms. We also found that cumanin and psilostachyin exhibited an additive effect in their trypanocidal activity when these two drugs were tested together. Cumanin has leishmanicidal activity with growth inhibition values greater than 80% at a concentration of 5 µg/ml (19 µM), against both L. braziliensis and L. amazonensis promastigotes. In an in vivo model of T. cruzi infection, cumanin was more active than benznidazole, producing an 8-fold reduction in parasitemia levels during the acute phase of the infection compared with the control group, and more importantly, a reduction in mortality with 66% of the animals surviving, in comparison with 100% mortality in the control group. Cumanin also showed nontoxic effects at the doses assayed in vivo, as determined using markers of hepatic damage.
Collapse
Affiliation(s)
- Valeria P. Sülsen
- Cátedra de Farmacognosia, IQUIMEFA (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Silvia I. Cazorla
- Cátedra de Inmunología, IDEHU (UBA-CONICET), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina and Instituto de Microbiología y Parasitología Médica, IMPaM (UBA-CONICET), Facultad de Medicina, Buenos Aires, Argentina
| | - Fernanda M. Frank
- Cátedra de Inmunología, IDEHU (UBA-CONICET), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina and Instituto de Microbiología y Parasitología Médica, IMPaM (UBA-CONICET), Facultad de Medicina, Buenos Aires, Argentina
| | - Laura C. Laurella
- Cátedra de Farmacognosia, IQUIMEFA (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Liliana V. Muschietti
- Cátedra de Farmacognosia, IQUIMEFA (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Cesar A. Catalán
- INQUINOA-CONICET, Instituto de Química Orgánica, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, San Miguel de Tucumán, Argentina
| | - Virginia S. Martino
- Cátedra de Farmacognosia, IQUIMEFA (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
- * E-mail: (VSM); r (ELM)
| | - Emilio L. Malchiodi
- Cátedra de Inmunología, IDEHU (UBA-CONICET), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina and Instituto de Microbiología y Parasitología Médica, IMPaM (UBA-CONICET), Facultad de Medicina, Buenos Aires, Argentina
- * E-mail: (VSM); r (ELM)
| |
Collapse
|
243
|
Trypanocide, cytotoxic, and anti-Candida activities of natural products: Hyptis martiusii Benth. Eur J Integr Med 2013. [DOI: 10.1016/j.eujim.2013.06.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
244
|
Hargrove TY, Wawrzak Z, Alexander PW, Chaplin JH, Keenan M, Charman SA, Perez CJ, Waterman MR, Chatelain E, Lepesheva GI. Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity. J Biol Chem 2013; 288:31602-15. [PMID: 24047900 DOI: 10.1074/jbc.m113.497990] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Chagas disease, caused by the eukaryotic (protozoan) parasite Trypanosoma cruzi, is an alarming emerging global health problem with no clinical drugs available to treat the chronic stage. Azole inhibitors of sterol 14α-demethylase (CYP51) were proven effective against Chagas, and antifungal drugs posaconazole and ravuconazole have entered clinical trials in Spain, Bolivia, and Argentina. Here we present the x-ray structures of T. cruzi CYP51 in complexes with two alternative drug candidates, pyridine derivatives (S)-(4-chlorophenyl)-1-(4-(4-(trifluoromethyl)phenyl)-piperazin-1-yl)-2-(pyridin-3-yl)ethanone (UDO; Protein Data Bank code 3ZG2) and N-[4-(trifluoromethyl)phenyl]-N-[1-[5-(trifluoromethyl)-2-pyridyl]-4-piperi-dyl]pyridin-3-amine (UDD; Protein Data Bank code 3ZG3). These compounds have been developed by the Drugs for Neglected Diseases initiative (DNDi) and are highly promising antichagasic agents in both cellular and in vivo experiments. The binding parameters and inhibitory effects on sterol 14α-demethylase activity in reconstituted enzyme reactions confirmed UDO and UDD as potent and selective T. cruzi CYP51 inhibitors. Comparative analysis of the pyridine- and azole-bound CYP51 structures uncovered the features that make UDO and UDD T. cruzi CYP51-specific. The structures suggest that although a precise fit between the shape of the inhibitor molecules and T. cruzi CYP51 active site topology underlies their high inhibitory potency, a longer coordination bond between the catalytic heme iron and the pyridine nitrogen implies a weaker influence of pyridines on the iron reduction potential, which may be the basis for the observed selectivity of these compounds toward the target enzyme versus other cytochrome P450s, including human drug-metabolizing P450s. These findings may pave the way for the development of novel CYP51-targeted drugs with optimized metabolic properties that are very much needed for the treatment of human infections caused by eukaryotic microbial pathogens.
Collapse
Affiliation(s)
- Tatiana Y Hargrove
- From the Department of Biochemistry, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232
| | | | | | | | | | | | | | | | | | | |
Collapse
|
245
|
Higginbotham SJ, Arnold AE, Ibañez A, Spadafora C, Coley PD, Kursar TA. Bioactivity of fungal endophytes as a function of endophyte taxonomy and the taxonomy and distribution of their host plants. PLoS One 2013; 8:e73192. [PMID: 24066037 PMCID: PMC3774686 DOI: 10.1371/journal.pone.0073192] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Accepted: 07/18/2013] [Indexed: 11/21/2022] Open
Abstract
Fungal endophytes--fungi that grow within plant tissues without causing immediate signs of disease--are abundant and diverse producers of bioactive secondary metabolites. Endophytes associated with leaves of tropical plants are an especially exciting and relatively untapped source of novel compounds. However, one major challenge in drug discovery lies in developing strategies to efficiently recover highly bioactive strains. As part of a 15-year drug discovery project, foliar endophytes were isolated from 3198 plant samples (51 orders, 105 families and at least 232 genera of angiosperms and ferns) collected in nine geographically distinct regions of Panama. Extracts from culture supernatants of >2700 isolates were tested for bioactivity (in vitro percent inhibition of growth, % IG) against a human breast cancer cell line (MCF-7) and the causative agents of malaria, leishmaniasis, and Chagas' disease. Overall, 32.7% of endophyte isolates were highly active in at least one bioassay, including representatives of diverse fungal lineages, host lineages, and collection sites. Up to 17% of isolates tested per assay were highly active. Most bioactive strains were active in only one assay. Fungal lineages differed in the incidence and degree of bioactivity, as did fungi from particular plant taxa, and greater bioactivity was observed in endophytes isolated from plants in cloud forests vs. lowland forests. Our results suggest that using host taxonomy and forest type to tailor plant collections, and selecting endophytes from specific orders or families for cultivation, will markedly increase the efficiency and efficacy of discovering bioactive metabolites for particular pharmaceutical targets.
Collapse
Affiliation(s)
| | - A. Elizabeth Arnold
- School of Plant Sciences, University of Arizona, Tucson, Arizona, United States of America
| | - Alicia Ibañez
- Smithsonian Tropical Research Institute, Panama, Republic of Panama
| | - Carmenza Spadafora
- Instituto de Investigaciones Científicas y Servicios de Alta Tecnología, Panama, Republic of Panama
| | - Phyllis D. Coley
- Smithsonian Tropical Research Institute, Panama, Republic of Panama
- Department of Biology, University of Utah, Salt Lake City, Utah, United States of America
| | - Thomas A. Kursar
- Smithsonian Tropical Research Institute, Panama, Republic of Panama
- Department of Biology, University of Utah, Salt Lake City, Utah, United States of America
| |
Collapse
|
246
|
Phytochemical, antimicrobial and antiprotozoal evaluation of Garcinia mangostana pericarp and α-mangostin, its major xanthone derivative. Molecules 2013; 18:10599-608. [PMID: 24002136 PMCID: PMC6270423 DOI: 10.3390/molecules180910599] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 08/21/2013] [Accepted: 08/28/2013] [Indexed: 11/17/2022] Open
Abstract
Five xanthone derivatives and one flavanol were isolated from the dichloromethane extract of Garcinia mangostana. Dichloromethane, ethyl acetate extract and the major xanthone (α-mangostin) were evaluated in vitro against erythrocytic schizonts of Plasmodium falciparum, intracellular amastigotes of Leishmania infantum and Trypanosoma cruzi and free trypomastigotes of T. brucei. The major constituent α-mangostin was also checked for antimicrobial potential against Candida albicans, Escherichia coli, Pseudomonas aeruginosa, Bacillius subtilis, Staphylococcus aureus, Mycobacterium smegmatis, M. cheleneoi, M. xenopi and M. intracellulare. Activity against P.falciparum (IC50 2.7 μg/mL) and T. brucei (IC50 0.5 μg/mL) were observed for the dichloromethane extract, however, with only moderate selectivity was seen based on a parallel cytotoxicity evaluation on MRC-5 cells (IC50 9.4 μg/mL). The ethyl acetate extract was inactive (IC50 > 30 µg/mL). The major constituent α-mangostin showed rather high cytotoxicity (IC50 7.5 µM) and a broad but non-selective antiprotozoal and antimicrobial activity profile. This in vitro study endorses that the antiprotozoal and antimicrobial potential of prenylated xanthones is non-conclusive in view of the low level of selectivity.
Collapse
|
247
|
Fonseca-Berzal C, Merchán Arenas DR, Romero Bohórquez AR, Escario JA, Kouznetsov VV, Gómez-Barrio A. Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase. Bioorg Med Chem Lett 2013; 23:4851-6. [DOI: 10.1016/j.bmcl.2013.06.079] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2013] [Revised: 06/24/2013] [Accepted: 06/27/2013] [Indexed: 11/16/2022]
|
248
|
Sykes ML, Avery VM. Approaches to Protozoan Drug Discovery: Phenotypic Screening. J Med Chem 2013; 56:7727-40. [DOI: 10.1021/jm4004279] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Melissa L. Sykes
- Discovery Biology, Eskitis Institute
for Drug Discovery, Griffith University, Nathan, Queensland, Australia
| | - Vicky M. Avery
- Discovery Biology, Eskitis Institute
for Drug Discovery, Griffith University, Nathan, Queensland, Australia
| |
Collapse
|
249
|
Trypanocidal activity of thioamide-substituted imidazoquinolinone: electrochemical properties and biological effects. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2013; 2013:945953. [PMID: 23935690 PMCID: PMC3723252 DOI: 10.1155/2013/945953] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/25/2013] [Accepted: 05/30/2013] [Indexed: 11/22/2022]
Abstract
Three thioamide-substituted imidazoquinolinone, which possess a heterocyclic center similar to tryptanthrin and are named C1, C2, and C3, were studied regarding (a) their in vitro anti-Trypanosoma cruzi activity, (b) their cytotoxicity and electrochemical behaviour, and (c) their effect on cell viability, redox state, and mitochondrial function. The assayed compounds showed a significant activity against the proliferative forms, but only C1 showed activity on the trypomastigote form (for C1, IC50 epi = 1.49 μM; IC50 amas = 1.74 μM; and IC50 try = 34.89 μM). The presence of an antioxidant compound such as ascorbic acid or dithiotreitol induced a threefold increase in the antiparasitic activity, whereas glutathione had a dual effect depending on its concentration. Our results indicate that these compounds, which exhibited low toxicity to the host cells, can be reduced inside the parasite by means of the pool of low molecular weight thiols, causing oxidative stress and parasite death by apoptosis. The antiparasitic activity of the compounds studied could be explained by a loss of the capacity of the antioxidant defense system of the parasite to keep its intracellular redox state. C1 could be considered a good candidate for in vivo evaluation.
Collapse
|
250
|
In vitro antiprotozoal activity of triterpenoid constituents of Kleinia odora growing in Saudi Arabia. Molecules 2013; 18:9207-18. [PMID: 23912274 PMCID: PMC6269755 DOI: 10.3390/molecules18089207] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2013] [Revised: 07/28/2013] [Accepted: 07/29/2013] [Indexed: 11/16/2022] Open
Abstract
Two lupane and four ursane triterpenes, namely epilupeol (1), lupeol acetate (2), ursolic acid (3), brein (4), 3β 11α-dihydroxy urs-12-ene (5) and ursolic acid lactone (6) were isolated from aerial parts of Kleinia odora and identified. Compounds 1 and 3–6 were isolated for the first time from K. odora. The triterpene constituents were investigated for antiprotozoal potential against erythrocytic schizonts of Plasmodium falciparum, intracellular amastigotes of Leishmania infantum and Trypanosoma cruzi and free trypomastigotes of T. brucei. Cytotoxicity was determined against MRC-5 fibroblasts to assess selectivity. The ursane triterpenes were found to be active against more than one type of the tested parasites, with the exception of compound 6. This is also the first report on the occurrence of ursane type triterpenes in the genus Kleinia and their antiprotozoal potential against P. falciparum, L. infantum, T. cruzi, and T. brucei.
Collapse
|